Canaccord Genuity reissued their buy rating on shares of ReWalk Robotics Ltd (NASDAQ:RWLK) in a report published on Monday. They currently have a $3.00 price objective on the medical device company’s stock.

“We maintain our BUY rating on ReWalk Robotics following Q3/17 results. ReWalk reported revenues of $1.7M, in line with preliminary results announced in October. Although the shipment of 16 systems was well below our expectation for 40 systems, ReWalk posted a solid top-line beat driven by a favorable mix of system purchases and rental conversions in the quarter. Despite the weaker than anticipated system placements, we were encouraged to see another quarter of increased demand and another positive coverage reimbursement win in Germany with the DGUV. We continue to think 2017 can be a transitional year for ReWalk as they gain momentum with expanded reimbursement.”,” the firm’s analyst wrote.

Several other equities research analysts also recently weighed in on RWLK. Jefferies Group LLC reduced their price objective on shares of ReWalk Robotics from $8.00 to $5.00 and set a buy rating for the company in a report on Friday, November 3rd. Oppenheimer Holdings, Inc. set a $4.00 price objective on shares of ReWalk Robotics and gave the stock a buy rating in a report on Friday, August 4th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $3.00.

ReWalk Robotics (NASDAQ:RWLK) traded up $0.02 on Monday, reaching $1.40. The company had a trading volume of 51,493 shares, compared to its average volume of 346,061. ReWalk Robotics has a twelve month low of $1.10 and a twelve month high of $3.60. The company has a quick ratio of 1.65, a current ratio of 2.02 and a debt-to-equity ratio of 7.46.

ReWalk Robotics (NASDAQ:RWLK) last posted its quarterly earnings data on Thursday, November 2nd. The medical device company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.10. The business had revenue of $1.70 million during the quarter, compared to the consensus estimate of $1.63 million. ReWalk Robotics had a negative net margin of 346.14% and a negative return on equity of 568.25%. The company’s quarterly revenue was up 21.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.62) earnings per share. research analysts expect that ReWalk Robotics will post -1.14 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://theolympiareport.com/2017/11/10/rewalk-robotics-rwlk-buy-rating-reiterated-at-canaccord-genuity.html.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Advisor Group Inc. lifted its holdings in ReWalk Robotics by 1,495.6% in the 3rd quarter. Advisor Group Inc. now owns 181,900 shares of the medical device company’s stock valued at $264,000 after acquiring an additional 170,500 shares during the last quarter. Essex Investment Management Co. LLC lifted its holdings in ReWalk Robotics by 328.7% in the 3rd quarter. Essex Investment Management Co. LLC now owns 156,981 shares of the medical device company’s stock valued at $228,000 after acquiring an additional 120,362 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in ReWalk Robotics by 61.7% in the 1st quarter. Renaissance Technologies LLC now owns 78,600 shares of the medical device company’s stock valued at $165,000 after acquiring an additional 30,000 shares during the last quarter. 3.81% of the stock is owned by institutional investors.

About ReWalk Robotics

ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement.

Receive News & Ratings for ReWalk Robotics Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReWalk Robotics Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.